Uterine Artery Embolization for Symptomatic Fibroids: Evidence‑Based Guidelines

Procedure Overview

• Uterine artery embolization (UAE) is a minimally invasive, transfemoral or transradial arterial technique that delivers embolic agents (gelatin, microspheres, coils) to occlude uterine arteries, causing ischemic necrosis and involution of fibroids (American College of Radiology) 1, 2.
• Both uterine arteries are selectively catheterized and embolized, with the catheter positioned distal to nontarget branches (American College of Radiology) 3.
• The procedural goal is complete occlusion of all distal uterine‑artery branches feeding the leiomyomas (American College of Radiology) 3.
• UAE is performed under conscious sedation (American College of Radiology) 3.
• Particulate embolic agents are used to achieve distal embolization (American College of Radiology) 3.

Candidate Selection

Indications

• UAE is indicated for women with symptomatic uterine fibroids causing bulk symptoms (pressure, pain, fullness, bladder or bowel complaints) and/or heavy menstrual bleeding (American College of Radiology) 1, 2, 4.

Pre‑Procedure Workup

• A complete gynecologic evaluation, including Pap smear every 3 years, is required (American College of Radiology) 3.
• Endometrial biopsy should be performed when menometrorrhagia is present (American College of Radiology) 3.
• Cross‑sectional imaging—preferably MRI—to confirm leiomyoma diagnosis and exclude other pelvic pathology is recommended (American College of Radiology) 3.

Contraindications

• Absolute contraindications: viable pregnancy and active pelvic inflammatory disease (American College of Radiology) 3.
• Relative considerations: women desiring future fertility must be counseled about limited long‑term data; recent evidence shows high live‑birth rates (73–81 %) after UAE (American College of Radiology) 1, 2.
• The FEMME trial demonstrated no significant difference in ovarian‑reserve biomarkers between UAE and myomectomy (American College of Radiology) 1, 2.

Immediate Post‑Procedure Care

• Patients should be monitored closely for the first 24–48 hours after discharge for pain, nausea, and potential complications (American College of Radiology) 3.
• Post‑embolization syndrome (flu‑like symptoms with pain, nausea, fever, leukocytosis) is common and usually resolves within the first week (American College of Radiology) 1, 2, 4.

Follow‑Up Schedule

• Clinical reevaluation is advised at 3–6 months post‑procedure to assess treatment efficacy (American College of Radiology) 3.
• Imaging (often MRI) may be performed to quantify fibroid‑volume reduction and detect incomplete infarction (American College of Radiology) 3.
• MRI after UAE is specifically recommended to confirm adequate fibroid infarction and to exclude occult uterine sarcoma (American College of Radiology) 3.

Expected Outcomes

Symptom Relief & Fibroid Reduction

• Clinical success rates ranging from 81 % to 100 % have been reported (American College of Radiology) 3.
• Average fibroid‑size reduction exceeds 50 % at 5 years (American College of Radiology) 1, 2, 4.
• Patients experience persistent reductions in pain and heavy menstrual bleeding since the first published series in 1995 (American College of Radiology) 1, 2, 4.

Comparative Effectiveness (UAE vs. Myomectomy)

• UAE is equally effective at reducing heavy menstrual bleeding compared with myomectomy at 4 years (American College of Radiology) 1, 2.
• UAE is associated with a lower risk of blood transfusion and shorter hospital stays relative to myomectomy (American College of Radiology) 1, 2.
• The incidence of new fibroid formation is significantly lower after UAE than after myomectomy (American College of Radiology) 1, 2.
• Quality‑of‑life scores and re‑intervention rates at 4 years are not significantly different between the two modalities (American College of Radiology) 1, 2.

Long‑Term Re‑intervention

• Secondary hysterectomy occurs in 28 % of patients at 5 years and 35 % at 10 years (EMMY trial, which did not permit repeat embolization) (American College of Radiology) 1, 2, 4.

Complications & Safety Considerations

• Pelvic pain is a common post‑procedure symptom (American College of Radiology) 1, 2, 4.
• Vaginal expulsion of submucosal fibroids occurs in approximately 5 % of patients; at‑risk cases can be identified by pre‑embolization hysteroscopy (American College of Radiology) 1, 2.
• Post‑embolization syndrome, as described above, is a recognized complication (American College of Radiology) 1, 2, 4.
• Approximately 1 in 350 women treated for presumed fibroids harbors an unsuspected uterine sarcoma; MRI follow‑up is essential to exclude this diagnosis (American College of Radiology) 3.

Fertility & Pregnancy

• Pregnancy after UAE is possible; patients should receive counseling (American College of Radiology) 5, 4.
• Prospective studies report high live‑birth rates (10 / 12 pregnancies) with low miscarriage rates (1 / 12) (American College of Radiology) 1, 2.
• A retrospective cohort demonstrated a live‑birth rate of 73 % (109 / 148) with a miscarriage rate of 17.5 % (American College of Radiology) 1, 2.

All statements are supported by the cited references and reflect the current evidence base as reported by the American College of Radiology.

Radiological Management of Uterine Fibroids

Primary Radiological Treatment: Uterine Artery Embolization

• The American College of Radiology recommends uterine artery embolization (UAE) as the primary radiological treatment for symptomatic uterine fibroids, achieving >50% fibroid volume reduction at 5 years with high patient satisfaction rates comparable to hysterectomy 6, 7
• Comprehensive gynecologic workup, including Pap smear and endometrial biopsy if menometrorrhagia is present, is required for all patients before UAE 6
• Cross-sectional imaging, preferably MRI, is mandatory to confirm leiomyoma diagnosis and exclude other pelvic pathology 6
• Absolute contraindications for UAE include viable pregnancy and active pelvic inflammatory disease 6
• The goal of UAE is complete occlusion of all distal uterine artery branches feeding the leiomyomas using particulate embolic agents 6
• Average fibroid size reduction exceeds 50% at 5 years, typically sufficient to relieve bulk symptoms including bladder compression 8
• UAE causes arterial occlusion, ischemic necrosis, and fibroid involution 8
• Patient satisfaction rates exceed 90% at 2-year follow-up, comparable to hysterectomy 9
• Significantly shorter hospitalization and faster return to work compared to surgical options 9
• Reintervention rate at 5 years is 28% and 35% at 10 years 8
• Close monitoring for 24-48 hours after discharge for pain control and potential complications is necessary 6, 10
• Post-embolization syndrome, characterized by fever, pain, and nausea, is common and typically resolves within the first week 10
• Reevaluation at 3-6 months to assess treatment efficacy is recommended 6
• MRI after UAE is specifically recommended to ensure adequate fibroid infarction and exclude underlying leiomyosarcoma 6

Alternative Radiological Treatment: MR-Guided Focused Ultrasound Surgery (MRgFUS)

• The American College of Radiology suggests MRgFUS as a non-invasive alternative to UAE for appropriately selected patients 7
• Limited evidence exists regarding the use of MRgFUS in patients with concurrent adenomyosis 7

Special Population: Adenomyosis with Fibroids

• Prospective cohort studies support UAE for patients with adenomyosis and fibroids who fail conservative measures and desire uterus-preserving therapy 7
• Improvement in quality of life and symptom scores has been demonstrated, especially when fibroids predominate 7
• Hysterectomy rate for persistent symptoms at up to 7-year follow-up is 18% 7
• Meta-analysis shows 94% short-term and 85% long-term symptom improvement with 7% hysterectomy rate 7

Comparative Effectiveness: UAE vs. Hysterectomy

• No significant difference in quality-of-life scores at 2-year and 5-year follow-up between UAE and hysterectomy 9
• UAE provides significantly greater short-term benefits, including shorter hospital stay and decreased blood loss 9

Common Pitfalls and Caveats

• Approximately 1 in 350 women undergoing treatment for presumed fibroids has unsuspected uterine sarcoma 6
• MRI follow-up is essential to exclude leiomyosarcoma, not just assess treatment efficacy 6
• Fibroid expulsion, particularly submucosal fibroids, is a potential complication 8
• Vessel injury requiring activity restrictions is a possible complication 10
• Hysteroscopic myomectomy is preferred for pedunculated submucosal fibroids <5 cm in fertility-desiring patients 7